Superworth

Organogenesis price to free cash flow ORGO

Market value divided by free cash flow over the last twelve months, since 2021.

Today, Nov 2, 2026
4.7×
5-year median
43.9×
Against its 5-year history
0th
percentile: 0 is its lowest day, 100 its highest
5-year range
4.7× to 189×
Peer median
11.4×

Organogenesis' price to free cash flow is 4.7× as of Nov 2, 2026.

That is below its 5-year median of 43.9×, lower than on 100% of days in the last 5 years.

Over that time it ranged from 4.7× in Nov 2026 to 189× in Feb 2025.

The median for 10 large drugmakers of a similar size is 11.4×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.7×4.7×20.0×
2025160×103×189×
2024109×38.4×138×
202347.9×47.9×56.1×
202253.9×18.2×57.7×
202133.6×33.6×84.1×

Against its peers

Companies in Drug Manufacturers - General nearest Organogenesis' size, closest first, today.

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Organogenesis

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.